Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Jasman who wrote (722)	2/13/1998 8:02:00 AM
From: Dr. John M. de Castro	Read Replies (3) \| Respond to of 887

DepoCyt prolongs life. It doesn't kill people. I think that you're misinterpreting the 2 deaths in the Phase IV. The patients involved are very sick. They are all terminal with metastasized cancer. DepoCyt is used to treat one of the sites that the cancer spreads to, the CNS. It is very effective in treating these metastases. It it at least as good as the best available treatment and probably better. The 2 deaths that DEPO reported are to be expected and they were from other causes, not DepoCyt. The Phase IV is an open label trial that does not have a methotrexate control group. If it did, you would probably see a comparable or higher death rate in the controls. John de C